Immunogenicity and safety of two-dose or three-dose regimens of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis: a randomised clinical trial
Authors
Yawen Zhu
Gang Zeng (ORCID: https://orcid.org/0000-0002-2954-9051)
Immunogenicity and safety of two-dose or three-dose regimens of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis: a randomised clinical trial
Yawen Zhu, Gang Zeng, Zhuopei Li, Gao Chunjing et al.
Journal
Expert Review of Vaccines
Topics
SARS-CoV-2 and COVID-19 Research
article
Immunogenicity and safety of two-dose or three-dose regimens of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis: a randomised clinical trial
Jiangsu University (CN), China Pharmaceutical University (CN), Xuzhou Medical College (CN), Nantong University (CN), Sinovac Biotech (CN), Xinjiang Uygur Autonomous Region Disease Prevention and Control Center (CN), Huaian First People’s Hospital (CN), Xuzhou Cancer Hospital (CN), Zhongda Hospital Southeast University (CN), Jiangsu Provincial Center for Disease Control and Prevention (CN), The Affiliated Taizhou People's Hospital of Nanjing Medical University (CN), Second People’s Hospital of Huai’an (CN), The First People’s Hospital of Lianyungang (CN), County Hospital (GB), Taiwan Centers for Disease Control (TW), Southeast University (CN), Nanjing Medical University (CN)